OncoMatch/Clinical Trials/NCT06250959
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
Is NCT06250959 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Blinatumomab and Doxorubicin for all, adult.
Treatment: Blinatumomab · Doxorubicin — In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as induction therapy. The clinical remission rate, MRD negative rate and treaty-related adverse reactions were evaluated.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: BCR fusion
Ph-(BCR-ABL1 negative)B-ALL was diagnosed according to WHO diagnostic criteria
Disease stage
Required: Stage NEWLY DIAGNOSED
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Lab requirements
Kidney function
endogenous creatinine clearance ≧30ml/min
Liver function
total bilirubin ≦ 3 times the upper limit of normal; Alanine aminotransferase ≦ 3 times upper limit of normal; Aspartate aminotransferase ≦ 3 times upper limit of normal (except considering leukemia infiltration)
Cardiac function
Patients with grade 2 or higher heart failure excluded
Liver function: total bilirubin ≦ 3 times the upper limit of normal; Alanine aminotransferase ≦ 3 times upper limit of normal; Aspartate aminotransferase ≦ 3 times upper limit of normal (except considering leukemia infiltration); Renal function: endogenous creatinine clearance ≧30ml/min; Patients with grade 2 or higher heart failure excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06250959 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require BCR?
Yes, BCR fusion is a required biomarker for enrollment.
What disease stage is eligible?
Stage NEWLY DIAGNOSED is required.
Is there an age limit?
Yes. Patients must be 65 years or younger and at least 15 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify